The FDA has granted accelerated approval to asciminib for newly diagnosed, Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.
The IASLC Academy is a prestigious program geared toward early-career physicians worldwide who aspire to pursue academic careers in thoracic oncology.
Joshua K. Sabari, MD, discusses the efficacy outcomes from the Ideate-Lung02 trial, noting the 52.4% ORR, 5.9-month median DOR, and 12.2-month OS and emphasizing that…
Journal of Neuro-Oncology – Posterior fossa tumors account for half of all childhood brain tumors, prompting the search for effective and affordable interventions to combat…
An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer treated with pralsetinib.
Panelists discuss how to operationalize bispecific antibody (BsAb) therapy in community practices, summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their…
Ichiro Kinoshita, MD, PhD, Hokkaido University Hospital, Sapporo, Japan, discusses findings from the Phase II MYTHOS trial (jRCT2011210017), evaluating trastuzumab deruxtecan (T-DXd) in HER2-positive recurrent/metastatic…
Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer with BRCA2 alterations.
Study data show that no patient with a response required opioids after a 24-hour post-procedure follow-up.
